Phase III results for a new oral drug to treat patients with IBS and diarrhoea show a decrease in symptoms compared to placebo, but any benefit will need to be considered in the context of side effects and risks, the authors say. Marketed by Furiex Pharmaceuticals, an affiliate of Allergan, eluxadoline (Viberzi) works on the ...
New oral IBS drug improves symptoms
By Nicola Garrett
21 Jan 2016